Winfried F Pickl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7386739/publications.pdf

Version: 2024-02-01

111

all docs

citations h-index g-index

111 111 8607
docs citations times ranked citing authors

114465

63

#	Article	IF	CITATIONS
1	Neutralization of SARSâ€CoVâ€2 requires antibodies against conformational receptorâ€binding domain epitopes. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 230-242.	5.7	45
2	Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma. Vaccines, 2022, 10, 374.	4.4	5
3	Omicron: A SARSâ€CoVâ€2 variant of real concern. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1616-1620.	5.7	14
4	Characterization of the antibody response to SARSâ€CoVâ€2 in a mildly affected pediatric population. Pediatric Allergy and Immunology, 2022, 33, e13737.	2.6	5
5	Vaccine based on folded receptor binding domainâ€PreS fusion protein with potential to induce sterilizing immunity to SARSâ€CoVâ€2 variants. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2431-2445.	5.7	16
6	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Frontiers in Immunology, 2022, 13, .	4.8	24
7	Combined assessment of S―and Nâ€specific <scp>lL</scp> â€2 and <scp>lL</scp> â€13 secretion and <scp>CD69</scp> neoâ€expression for discrimination of post–infection and postâ€vaccination cellular <scp>SARSâ€CoV</scp> â€2â€specific immune response. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3408-3425.	5.7	7
8	Art v $1\mathrm{lgE}$ epitopes of patients and humanized mice are conformational. Journal of Allergy and Clinical Immunology, 2022, 150, 920-930.	2.9	2
9	Past, present, and future of allergen immunotherapy vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 131-149.	5.7	66
10	Attenuation of canonical NFâ€ĤB signaling maintains function and stability of human Treg. FEBS Journal, 2021, 288, 640-662.	4.7	9
11	Antibodies in serum of convalescent patients following mild COVIDâ€19 do not always prevent virusâ€receptor binding. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 878-883.	5.7	39
12	Immunological imprint of COVIDâ€19 on human peripheral blood leukocyte populations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 751-765.	5.7	71
13	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. FASEB Journal, 2021, 35, e21217.	0.5	9
14	SARS-CoV-2 mutations in MHC-l-restricted epitopes evade CD8 ⁺ T cell responses. Science Immunology, 2021, 6, .	11.9	143
15	Associations between specific IgE sensitization to 26 respiratory allergen molecules and HLA class II alleles in the EGEA cohort. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2575-2586.	5.7	9
16	Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. ACS Synthetic Biology, 2021, 10, 1184-1198.	3.8	9
17	Tick-Borne Encephalitis Specific Lymphocyte Response after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Humoral Immunity after Vaccination. Vaccines, 2021, 9, 908.	4.4	5
18	Preventive Administration of Non-Allergenic Bet ν 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet ν 1. Frontiers in Immunology, 2021, 12, 744544.	4.8	8

#	Article	IF	CITATIONS
19	Value of Autoantibody Expression During Long-Term Follow-Up in Paediatric ALL Patients After Allogeneic Haematopoietic Stem Cell Transplantation. Frontiers in Pediatrics, 2021, 9, 788360.	1.9	0
20	Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient—Addendum to the Genotype-Phenotype Puzzle. Journal of Clinical Immunology, 2020, 40, 223-226.	3.8	7
21	All the small things: How virusâ€like particles and liposomes modulate allergic immune responses. European Journal of Immunology, 2020, 50, 17-32.	2.9	12
22	Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation. Journal of Allergy and Clinical Immunology, 2020, 145, 958-967.e5.	2.9	11
23	Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity. Nature Immunology, 2020, 21, 756-765.	14.5	63
24	Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?. Frontiers in Immunology, 2020, 11, 1368.	4.8	21
25	Allergen alters ILâ€2/αILâ€2â€based Treg expansion but not tolerance induction in an allergenâ€specific mouse model. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1618-1629.	5.7	8
26	Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces. European Journal of Immunology, 2020, 50, 624-642.	2.9	21
27	Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. Haematologica, 2020, 105, e488.	3.5	17
28	Editorial: Challenges in Vaccinology. Frontiers in Immunology, 2020, 11, 632537.	4.8	2
29	Prevention of allergy by virusâ€like nanoparticles (<scp>VNP</scp>) delivering shielded versions of major allergens in a humanized murine allergy model. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 246-260.	5.7	31
30	Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. Frontiers in Immunology, 2019, 10, 1790.	4.8	12
31	Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. Nature Communications, 2019, 10, 3106.	12.8	48
32	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
33	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications, 2019, 10, 4186.	12.8	236
34	The making and function of CAR cells. Immunology Letters, 2019, 212, 53-69.	2.5	19
35	National Institutes of Health–Defined Chronic Graft-vsHost Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution. Frontiers in Immunology, 2019, 10, 1879.	4.8	14
36	Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice. EBioMedicine, 2018, 31, 66-78.	6.1	24

#	Article	IF	CITATIONS
37	Distinct epitope structures of defensinâ€like proteins linked to prolineâ€rich regions give rise to differences in their allergenic activity. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 431-441.	5.7	22
38	Blocking antibodies induced by allergenâ€specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 851-861.	5.7	19
39	Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 145-149.	1.5	13
40	Molecular Aspects of Allergens and Allergy. Advances in Immunology, 2018, 138, 195-256.	2.2	81
41	CD23 surface density on BÂcells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific TÂcells. Journal of Allergy and Clinical Immunology, 2017, 139, 290-299.e4.	2.9	62
42	Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. Scientific Reports, 2017, 7, 42191.	3.3	36
43	<i>MEF2C</i> -dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with <i>CDKN1B</i> deletions and a poor response to glucocorticoid therapy. Leukemia and Lymphoma, 2017, 58, 2895-2904.	1.3	19
44	The IL–10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory Tâ€cells. European Journal of Immunology, 2017, 47, 1256-1265.	2.9	70
45	Pharmacological targeting of allergen-specific T lymphocytes. Immunology Letters, 2017, 189, 27-39.	2.5	3
46	Murine models for mucosal tolerance in allergy. Seminars in Immunology, 2017, 30, 12-27.	5.6	12
47	A cellular platform for the evaluation of immune checkpoint molecules. Oncotarget, 2017, 8, 64892-64906.	1.8	48
48	Years in Review: Recent Progress in Cellular Allergology. International Archives of Allergy and Immunology, 2016, 169, 1-12.	2.1	8
49	On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy). International Archives of Allergy and Immunology, 2016, 170, 211-233.	2.1	30
50	RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nature Immunology, 2016, 17, 1352-1360.	14.5	115
51	Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens. Scientific Reports, 2016, 6, 31580.	3.3	22
52	The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation. Journal of Leukocyte Biology, 2016, 99, 583-594.	3.3	22
53	CD8+ T Cell Fate and Function Influenced by Antigen-Specific Virus-Like Nanoparticles Co-Expressing Membrane Tethered IL-2. PLoS ONE, 2015, 10, e0126034.	2.5	3
54	STAT3 governs hyporesponsiveness and granzyme Bâ€dependent suppressive capacity in human CD4 + T cells. FASEB Journal, 2015, 29, 759-771.	0.5	21

#	Article	IF	CITATIONS
55	CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 250-258.	2.0	47
56	Early-onset inflammatory bowel disease and common variable immunodeficiency–like disease caused by IL-21 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1651-1659.e12.	2.9	124
57	Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nature Communications, 2014, 5, 5360.	12.8	116
58	Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity. Scientific Reports, 2014, 4, 7438.	3.3	90
59	Fluorosomes: Fluorescent Virus-Like Nanoparticles that Represent a Convenient Tool to Visualize Receptor-Ligand Interactions. Sensors, 2013, 13, 8722-8749.	3.8	13
60	Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB Journal, 2012, 26, 2253-2276.	0.5	144
61	<scp>NI</scp> â€1: a novel canine mastocytoma model for studying drug resistance and <scp>I</scp> g <scp>ER</scp> â€dependent mast cell activation. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 858-868.	5.7	18
62	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. Blood, 2012, 120, 1760-1760.	1.4	0
63	Lipid Rafts, Pseudotyping, and Virus-Like Particles: Relevance of a Novel, Configurable, and Modular Antigen-Presenting Platform. International Archives of Allergy and Immunology, 2011, 154, 89-110.	2.1	16
64	Bet v 1–specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1–specific T-cell effector function in an activation-dependent manner. Journal of Allergy and Clinical Immunology, 2011, 127, 238-245.e3.	2.9	29
65	Human TCR Transgenic Bet v 1-Specific Th1 Cells Suppress the Effector Function of Bet v 1-Specific Th2 Cells. Journal of Immunology, 2011, 187, 4077-4087.	0.8	18
66	The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML. Blood, 2011, 118, 4414-4414.	1.4	0
67	5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,. Blood, 2011, 118, 3457-3457.	1.4	0
68	T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. Journal of Immunological Methods, 2010, 362, 131-141.	1.4	65
69	Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptorâ€igand interactions. FASEB Journal, 2010, 24, 1572-1582.	0.5	17
70	The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition Blood, 2010, 116, 3394-3394.	1.4	0
71	Nilotinib and Dasatinib Produce Synergistic Growth-Inhibitory Effects In Imatinib-Resistant CML Cells, Including Subclones Bearing the Multi-Resistant BCR/ABL Mutant T315I. Blood, 2010, 116, 2280-2280.	1.4	0
72	Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. Journal of Allergy and Clinical Immunology, 2009, 124, 121-128.	2.9	27

#	Article	IF	Citations
73	Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells Blood, 2009, 114, 1717-1717.	1.4	1
74	Assessment of the Potential of Immature CD19+CD21- B-Lymphocytes to Predict Response to Various Systemic Therapies in Chronic Graft-Versus-Host Disease Blood, 2009, 114, 2226-2226.	1.4	0
75	The capacity of the TNF family members 4â€1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. European Journal of Immunology, 2008, 38, 2678-2688.	2.9	86
76	Molecular and functional analysis of the antigen receptor of Art v 1–specific helper T lymphocytes. Journal of Allergy and Clinical Immunology, 2008, 121, 64-71.	2.9	31
77	Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art ν 1, the Major Mugwort Pollen Allergen. Journal of Immunology, 2008, 181, 3636-3642.	0.8	21
78	Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL) Blood, 2008, 112, 1616-1616.	1.4	0
79	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax $\hat{A}^{@}$) on Growth and Viability of Canine and Human Neoplastic Mast Cells. Blood, 2008, 112, 861-861.	1.4	0
80	Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells. Blood, 2008, 112, 3195-3195.	1.4	0
81	General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines. Journal of Virology, 2007, 81, 8666-8676.	3.4	35
82	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. Blood, 2007, 110, 1541-1541.	1.4	6
83	The Hsp32/HO-1-targeted drug SMA-ZnPP counteracts the proliferation and viability of neoplastic cells in solid tumors and hematologic neoplasms. Journal of Clinical Oncology, 2007, 25, 14122-14122.	1.6	3
84	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition Blood, 2007, 110, 3554-3554.	1.4	O
85	The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition Blood, 2007, 110, 1046-1046.	1.4	1
86	Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα Blood, 2007, 110, 3559-3559.	1.4	1
87	No evidence for dualism in function and receptors: PD‣2/B7â€DC is an inhibitory regulator of human T cell activation. European Journal of Immunology, 2006, 36, 1104-1113.	2.9	45
88	Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13144-13149.	7.1	54
89	Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML Blood, 2006, 108, 1901-1901.	1.4	1
90	Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT Blood, 2006, 108, 526-526.	1.4	5

#	Article	IF	Citations
91	Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis Blood, 2006, 108, 4323-4323.	1.4	0
92	Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease Blood, 2006, 108, 2881-2881.	1.4	0
93	The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells Blood, 2006, 108, 1437-1437.	1.4	0
94	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107 Blood, 2005, 106, 3516-3516.	1.4	1
95	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis Blood, 2005, 106, 3518-3518.	1.4	2
96	BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells Blood, 2005, 106, 4835-4835.	1.4	0
97	Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors Blood, 2005, 106, 1987-1987.	1.4	0
98	Molecular Characterization of Human 4lg-B7-H3, a Member of the B7 Family with Four lg-Like Domains. Journal of Immunology, 2004, 172, 2352-2359.	0.8	228
99	The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells Blood, 2004, 104, 1986-1986.	1.4	1
100	Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF Blood, 2004, 104, 2544-2544.	1.4	2
101	Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML Blood, 2004, 104, 2972-2972.	1.4	0
102	Lipid Rafts and Pseudotyping. Journal of Virology, 2001, 75, 7175-7183.	3.4	149
103	Neutrophil Granulocyte–committed Cells Can Be Driven to Acquire Dendritic Cell Characteristics. Journal of Experimental Medicine, 1998, 187, 1019-1028.	8.5	182
104	MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. Journal of Immunology, 1997, 158, 2107-15.	0.8	81
105	Expression of LA45 reactive β ₂ â€microglobulin free HLA Class I αâ€chains on activated Tâ€cells is regulated by internalization, constitutive and protein kinase C inducible release. Tissue Antigens, 1996, 48, 15-21.	1.0	21
106	Expression of β 2 â€microglobulinâ€free HLA class I αâ€chains on activated T cells requires internalization of HLA class I heterodimers. Immunology, 1996, 88, 104-109.	4.4	27
107	Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. Journal of Immunology, 1996, 157, 3850-9.	0.8	283
108	The soluble pool of beta 2-microglobulin free HLA class I alpha-chains. Qualitative and quantitative characterization. Journal of Immunology, 1993, 151, 2613-22.	0.8	24

#	Article	IF	CITATIONS
109	Association between IgE response against Bet v I, the major allergen of Birch Pollen, and HLA-DRB alleles. Human Immunology, 1992, 33, 259-265.	2.4	67